
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: DMAA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 4 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 9.95 - 10.27 | Updated Date 05/1/2025 |
52 Weeks Range 9.95 - 10.27 | Updated Date 05/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Drugs Made In America Acquisition Corp. Ordinary Shares
Company Overview
History and Background
Drugs Made In America Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It was founded in 2021.
Core Business Areas
- Special Purpose Acquisition Company (SPAC): Drugs Made In America Acquisition Corp. focuses on identifying and acquiring a target company. It does not have specific operations until it completes an acquisition.
Leadership and Structure
The company is led by a management team focused on identifying acquisition targets, typically in the healthcare or pharmaceutical sector. The organizational structure is typical of a SPAC, with a board of directors and executives responsible for deal sourcing and execution.
Top Products and Market Share
Key Offerings
- Blank Check Acquisition Target: The company's primary offering is the potential acquisition of an operating business. Market share is not applicable as it is a SPAC. Competitors include other SPACs searching for targets.
Market Dynamics
Industry Overview
The SPAC market is characterized by high competition and regulatory scrutiny. Success depends on identifying attractive acquisition targets and completing deals on favorable terms.
Positioning
Drugs Made In America Acquisition Corp. is positioned as a vehicle for a target company to go public. Competitive advantages depend on the team's deal-sourcing abilities and sector expertise.
Total Addressable Market (TAM)
The TAM is the total value of potential acquisition targets. Drugs Made In America Acquisition Corp.'s positioning with respect to TAM depends on its ability to identify and acquire a suitable target company.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Dedicated capital for acquisition
- Flexibility in deal structure
Weaknesses
- No operating history
- Dependence on finding suitable target
- Potential for shareholder dilution
Opportunities
- Acquisition of high-growth company
- Leveraging market trends
- Creating shareholder value
Threats
- Increased competition from other SPACs
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
Competitive Landscape
The competitive landscape is defined by the number of SPACs searching for targets and the attractiveness of available companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable prior to an acquisition.
Future Projections: Future projections depend on the target company's performance.
Recent Initiatives: Recent initiatives involve deal sourcing and due diligence.
Summary
Drugs Made In America Acquisition Corp. is a special purpose acquisition company aiming to identify and acquire a company, likely in the pharmaceutical industry. The companyu2019s success hinges on its ability to find and close a deal on favorable terms. It faces competition from other SPACs. The team needs to secure a promising target and needs to be weary of the increasing scrutiny of the SPAC process.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company press releases
Disclaimers:
This analysis is based on limited publicly available information and is subject to change. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Drugs Made In America Acquisition Corp. Ordinary Shares
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2025-02-25 | CEO & Executive Chairman Ms. Lynn Stockwell | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://dmaacorp.com |
Full time employees - | Website https://dmaacorp.com |
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.